Outcome of the Meeting of Board of Directors held on Wednesday, May 21, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.2 pts less than Nifty Microcap 250 and 5.2 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Genpharmasec's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Statutory auditor Abhishek S Tiwari & Associates issued an unmodified (clean) opinion on both sets of results. Standalone revenue grew ~8% YoY to Rs. 3,296 lakhs, while standalone PAT surged from Rs. 4.6 lakhs to Rs. 247 lakhs, driven by higher other income and lower other expenses. Consolidated FY25 PAT swung to a profit of Rs. 123 lakhs versus a Rs. 17 lakhs loss last year, though Q4 standalone showed a small dip in profit. The board also appointed Abhishek M Agrawal & Co. as internal auditor for FY26 and Jaymin Modi & Co. as secretarial auditor for a five-year term (FY26–FY30), subject to shareholder approval.
Clean audit opinion and sharp jump in full-year profitability are positives for shareholders, though the surge in profit is largely driven by non-operating income rather than core revenue growth. Cash and equivalents dropped sharply to Rs. 52 lakhs (from Rs. 292 lakhs) as funds were deployed into loans and investments, which investors should monitor closely.